Biotech Values

[DewDiligence]

Shire’s Vyvanse logged $129M in 3Q09 sales:

http://finance.yahoo.com/news/Shire-Continues-to-Deliver-prnews-2342937657.html?x=0&.v=101

This is not exactly blockbuster status, but I’m somewhat surprised Vyvanse is doing even this well—it strikes me as exactly the wrong kind of drug for today’s healthcare environment, where governments and third-party payers are increasingly demanding empirical evidence of a clinical benefit relative to older and cheaper options.

HGSI’s Albuferon is another such drug, IMO. If NVS is smart, they won’t expend a lot of marketing resources to promote it. (If NVS does not build a de novo marketing infrastructure for Albuferon, it lessens NVS’ ability to leverage SG&A expenses by developing or in-licensing other HCV compounds, which could have been a consideration in the IDX184 decision.)